| Literature DB >> 36204495 |
Oluka Pross Nagitta1, Marcia Mkansi2, Sylvia Desire Nyesiga3, George William Kajjumba4.
Abstract
Introduction: Malaria is a killer disease in the tropical environment; artemisinin-based combination therapies (ACTs) play a central role in treating malaria. Thus, the supply and presence of ACT drugs in hospitals are a key feature in the fight against malaria. Supply chain management literature has focused on the private sector, and less attention has been paid to the public sector, especially hospitals. Aim: This study uses an interdisciplinary lens in investigating how to boost the supply and distribution of ACTs to save lives in low-income countries, specifically in Uganda. Methodology: The study adopted a quantitative research design using a questionnaire as the data collection instrument. Of the 440-population size, 304 of the sample population participated in the study. The model was estimated using structural equation modeling (SEM) to establish the causal relationship among the variables.Entities:
Keywords: Malaria; logistics; low-income countries; mutual understanding; public health; supply chain coordination; top management
Year: 2021 PMID: 36204495 PMCID: PMC9413604 DOI: 10.1177/23992026211064711
Source DB: PubMed Journal: Med Access Point Care ISSN: 2399-2026
Figure 1.A conceptual model developed from the literature.
Reliability test based on 283 respondents and listwise deletion, based on all variables in the procedure.
| Group | CA
| No. of items |
|---|---|---|
| Strategic determinants | 0.817 | 10 |
| Operation determinants | 0.897 | 11 |
| Availability of ACTs
| 0.908 | 6 |
CA: Cronbach’s alpha.
Overall CA = 0.926.
Six items remained after deleting one item.
Demographical nature of the respondents.
| Variable | Category |
| % |
|---|---|---|---|
| Gender | Male | 135 | 47.7 |
| Female | 148 | 52.3 | |
| Age | 20–29 | 67 | 23.7 |
| 30–39 | 102 | 36.0 | |
| 40–49 | 76 | 26.9 | |
| 50+ | 38 | 13.4 | |
| Education | Certificate | 9 | 3.2 |
| Diploma | 68 | 24.0 | |
| Degree | 142 | 50.2 | |
| Master | 52 | 18.4 | |
| PhD | 12 | 4.2 | |
| Supply chain training | Yes | 83 | 29.3 |
| No | 196 | 69.3 | |
| Position | Senior manager | 32 | 11.3 |
| Middle manager | 60 | 21.2 | |
| Supervisor | 51 | 18.0 | |
| Officer | 140 | 49.5 | |
| Experience | <1 | 9 | 3.2 |
| 1–3 | 105 | 37.1 | |
| 4–6 | 116 | 41.0 | |
| 7–9 | 33 | 11.7 | |
| 10+ | 20 | 7.1 |
Validity and factor correlation matrix with the square root of AVE on the diagonal.
| Proposed model | CR | AVE | MSV | Operation | Strategy | Availability |
|---|---|---|---|---|---|---|
| Operational | 0.880 | 0.425 | 0.450 | 0.652 | ||
| Strategic | 0.788 | 0.297 | 0.527 | 0.671 |
| |
| Availability | 0.910 | 0.629 | 0.527 | 0.630 | 0.726 |
|
| Adjusted model | CR | AVE | MSV | Operation | Strategy | Availability |
| Operational | 0.891 | 0.523 | 0.391 |
| ||
| Strategic | 0.794 | 0.520 | 0.505 | 0.625 |
| |
| Availability | 0.910 | 0.629 | 0.552 | 0.622 | 0.643 |
|
AVE: average variance explained; CR: composite reliability; MSV: maximum shared variance.
Common method bias based on the percentage of variance = 63.90%. It was conducted by running maximum likelihood with Promax rotation.
Figure 2.CFA model.e: error in nth univariate variable; other variables are defined in Table 6.
Nomenclature of the item.
| OF03 | Existence of the Drug Therapeutic Committee |
| R01 | Adherence of timelines by stores to other units |
| MU01 | Staff awareness |
| MU02 | Staff coherence |
| MU03 | Mutual trust among staff |
| MU04 | Shared vision |
| RM02 | Relationships |
| RM03 | Joint decision on procurement planning |
| RM04 | Good relationship with suppliers |
| TM01 | Frequent feedback on stock status |
| TM02 | Support for online ordering |
| TM03 | Transport emergencies |
| TM04 | Guidelines |
| A01 | Timely delivery |
| A02 | Flexible ordering |
| A03 | Right quantities |
| A04 | Right quality standards |
| A05 | Orders met by the supplier |
| A06 | Improved stock levels |
Results of GOFI measures.
| Goodness-of-fit measure | Acceptable threshold | Hypothetical model | Revised model |
|---|---|---|---|
| RMSEA | <0.08 | 0.126 | 0.054 |
| GFI | >0.90 | 0.718 | 0.906 |
| AGFI | >0.90 | 0.645 | 0.874 |
| CFI | >0.90 | 0.807 | 0.966 |
| NFI | >0.90 | 0.774 | 0.929 |
| TLI | >0.90 | 0.780 | 0.959 |
| PCFI | >0.50 | 0.709 | 0.798 |
| PNFI | >0.50 | 0.681 | 0.768 |
RMSEA: root mean square error of approximation; GFI: goodness of fit index; AGFI: adjusted goodness of fit index; CFI: comparative fit index; NFI: normed fit index; TLI: Tucker–Lewis index; PCFI: parsimony comparative fit index; PNFI: parsimony normed fit index.
Figure 3.Path coefficients of the predictor model.
Figure 4.Initial SEM model.
Standardized regression weights and hypothesis test.
| Path | Estimate |
| Path | Estimate |
| ||||
|---|---|---|---|---|---|---|---|---|---|
| TM1 | <— | Strategy | 0.774 |
| MU4 | <— | Operation | 0.943 |
|
| TM2 | <— | Strategy | 0.764 |
| MU3 | <— | Operation | 0.929 |
|
| TM3 | <— | Strategy | 0.764 |
| MU2 | <— | Operation | 0.876 |
|
| TM4 | <— | Strategy | 0.759 |
| MU1 | <— | Operation | 0.784 |
|
| OF03 | <— | Strategy | 0.301 |
| A01 | <— | Availability | 0.727 |
|
| R01 | <— | Strategy | 0.265 |
| A02 | <— | Availability | 0.776 |
|
| RM4 | <— | Operation | 0.456 |
| A03 | <— | Availability | 0.851 |
|
| RM3 | <— | Operation | 0.494 |
| A04 | <— | Availability | 0.78 |
|
| RM2 | <— | Operation | 0.414 |
| A05 | <— | Availability | 0.825 |
|
| RM1 | <— | Operation | 0.486 |
| A06 | <— | Availability | 0.747 |
|
| Hypotheses | Path | Effect |
| Results | |||||
| H1a | Strategy→Availability | 0.612 |
| Supported | |||||
| H1b | Strategy→Operation | 0.599 |
| Supported | |||||
| H2 | Operation→Availability | 0.257 |
| Supported | |||||
| Indirect effect | Strategy→Operation→Availability | 0.156 | 0.056 | Not supported | |||||
TM: top management; MU: mutual understanding; OF: organizational factor; A: ACT (artemisinin-based combination therapy); R: responsiveness; RM: relationship management.
p < 0.001.